K. Fuchino

Facile Construction of an Amino-1,3-Oxazine Scaffold using Burgess Reagent Under Mild Conditions

K. Kusakabe, S. Yoshida, M. Masui, 2020 .

Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2.

D. Moechars, K. Kusakabe, N. Asada, 2019, Journal of medicinal chemistry.

Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective β-Secretase (BACE1) Inhibitors over BACE2.

D. Moechars, K. Kusakabe, Shinji Suzuki, 2021, Journal of medicinal chemistry.

Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.

H. Kai, Naomi Tamura, T. Kameyama, 2019, Bioorganic & medicinal chemistry letters.

Discovery of an Extremely Potent Thiazine-Based β-Secretase (BACE1) Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose.

K. Kusakabe, Shinji Suzuki, N. Asada, 2019, Journal of medicinal chemistry.

Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization.

Kenji Nakahara, Takahiko Yamamoto, K. Kusakabe, 2018, Journal of medicinal chemistry.

Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.

K. Kusakabe, Y. Kido, T. Fukushima, 2018, Journal of medicinal chemistry.